Article in American journal of physiology. Heart and circulatory physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Kelsey C MuirDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.ORCID 0000-0001-8768-5468
Christopher StoneDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.
Dwight D HarrisDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.
Meghamsh KanuparthyDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.
Mark BroadwinDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.ORCID 0000-0002-0393-9983
Jad HamzeDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.
Jun FengDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.ORCID 0000-0003-4762-7532
Frank W SellkeDivision of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.ORCID 0000-0002-8886-801X
Funding
Effect of Cardioplegia and Cardiopulmonary Bypass on Coronary Microvascular ReactivityR01HL046716 · NHLBI · RHODE ISLAND HOSPITAL · PI SELLKE, FRANK W · 1997 to 2023
$8.5M
Vascular Dysfunction in Myocardial Ischemia and Metabolic SyndromeR01HL128831 · NHLBI · RHODE ISLAND HOSPITAL · PI SELLKE, FRANK W, USHEVA-SIMIDJIYSKA, ANNY · 2016 to 2025
$5.7M
Cardiovascular Surgery Research TrainingT32HL160517 · NHLBI · RHODE ISLAND HOSPITAL · PI Frank W Sellke · 2022 to 2026
$1.5M
CaMKII and Endothelial SK Channel Function in Diabetic Coronary MicrocirculationR01HL176640 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI Jun Feng · 2025 to 2026
$1.3M
CaMKII and Endothelial SK Channel Function in Diabetic Coronary MicrocirculationR56HL169501 · NHLBI · RHODE ISLAND HOSPITAL · PI FENG, JUN · 2023 to 2023
$533k
HHS | National Institutes of Health (NIH) 1R01HL176640-01HHS | National Institutes of Health (NIH) 1R56HL169501-01HHS | National Institutes of Health (NIH) R01HL128831HHS | National Institutes of Health (NIH) R01HL46716HHS | National Institutes of Health (NIH) T32HL160517NHLBI NIH HHS R01 HL046716NHLBI NIH HHS R01 HL128831NHLBI NIH HHS R01 HL176640NHLBI NIH HHS R56 HL169501NHLBI NIH HHS T32 HL160517Rhode Island Hospital (RI Hospital) Armand D. Versaci Research Scholar in the Surgical Sciences Award
6 · The paper itself
Abstract
The search for effective adjuncts to procedural revascularization for patients with coronary artery disease (CAD) has revealed, after several successful outcomes trials, the substantial potential of glucagon-like peptide 1 (GLP-1) analogs such as semaglutide. Because this potential has not been mechanistically illuminated in the setting of CAD and metabolic syndrome, we used a large animal model to evaluate the cardiac consequences of GLP-1 receptor (GLP-1R) agonism. Sixteen Yorkshire swine, after provision of a high-fat diet for 5 wk to induce metabolic syndrome, underwent ameroid constrictor-mediated induction of focal CAD. Animals were then either randomized to receive semaglutide (SEM,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy. · full record | OpenQuestion